8-KRegulation FD

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Regulation FD Disclosure (Dec 20, 2024)

Filed December 20, 2024For Securities:VRTX

Summary

Vertex Pharmaceuticals announced a significant milestone with the U.S. Food and Drug Administration's approval of ALYFTREK™ (vanzacaftor/tezacaftor/deutivacaftor) on December 19, 2024. This new therapy targets cystic fibrosis (CF) in patients aged 6 and older who possess at least one F508del mutation or another responsive mutation in the CFTR gene. The approval represents a key advancement in Vertex's CF franchise and offers a new treatment option for a broad segment of the CF patient population. The company has also set the wholesale acquisition cost (WAC) for ALYFTREK in the United States at $370,269 annually, or $28,404 per 28-day pack. This pricing, while substantial, is typical for advanced therapies in the rare disease space and will be a crucial factor for payers and patients to consider. Investors will be closely watching market uptake and reimbursement dynamics for ALYFTREK as it launches.

Key Highlights

  • 1FDA approval of ALYFTREK™ (vanzacaftor/tezacaftor/deutivacaftor) for cystic fibrosis.
  • 2ALYFTREK targets patients aged 6+ with specific CFTR gene mutations (including F508del).
  • 3Approval date: December 19, 2024.
  • 4Annual U.S. Wholesale Acquisition Cost (WAC) set at $370,269.
  • 5Per 28-day pack cost established at $28,404.
  • 6This filing is made under Regulation FD.
  • 7The information is not deemed 'filed' for Section 18 liability purposes.

Frequently Asked Questions

ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor) is a newly approved medication by the FDA for the treatment of cystic fibrosis in individuals aged 6 years and older who have at least one F508del mutation or another mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to ALYFTREK.

The wholesale acquisition cost (WAC) for ALYFTREK in the United States has been established at $370,269 on an annual basis. This translates to $28,404 per 28-day pack.

The FDA approval of ALYFTREK is a major development for Vertex Pharmaceuticals, expanding its portfolio of treatments for cystic fibrosis and potentially reaching a broader patient population with its latest generation CFTR modulator therapy. It reinforces the company's leadership in the CF space.

ALYFTREK was approved by the U.S. Food and Drug Administration on December 19, 2024.